Krystal Biotech (NASDAQ:KRYS) Stock Price Down 3.1%

Krystal Biotech, Inc. (NASDAQ:KRYS) fell 3.1% during mid-day trading on Tuesday . The company traded as low as $187.62 and last traded at $188.21. 100,366 shares were traded during trading, a decline of 71% from the average session volume of 350,665 shares. The stock had previously closed at $194.27.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KRYS. HC Wainwright upped their price target on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research note on Wednesday, August 28th. Evercore ISI upped their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Citigroup restated a “neutral” rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Stifel Nicolaus increased their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $196.75.

Krystal Biotech Stock Down 2.6 %

The stock has a 50 day moving average of $196.09 and a 200 day moving average of $178.99. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of 101.21 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The business’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.25) EPS. As a group, analysts predict that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in the stock. Scout Investments Inc. acquired a new position in Krystal Biotech during the 1st quarter worth approximately $8,976,000. Sei Investments Co. increased its holdings in shares of Krystal Biotech by 128.3% during the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after buying an additional 18,968 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after acquiring an additional 35,632 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Krystal Biotech during the 1st quarter worth $3,175,000. Finally, Braidwell LP increased its holdings in Krystal Biotech by 153.2% in the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock worth $24,341,000 after purchasing an additional 118,703 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).